mri1867

(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a potent and selective antagonist of the cannabinoid receptor type 1 (CB1R) and inducible nitric oxide synthase (iNOS), exhibiting a binding affinity (Ki) of 5.7 nM specifically for CB1R. Due to its characteristics, (Rac)-Zevaquenabant holds promise as an investigative tool in liver fibrosis research.

Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).